ECEESPE2025 Poster Presentations Thyroid (141 abstracts)
miRNA expression profiles in thyroid tumors with nras q61r variant
Karolina Mastnikova 1 , Vlasta Kuklikova 1 , Barbora Bulanova 1 , Olivia Cillikova 1 , Katerina Vyhnalova 1 , Marie Rodova 1 , Eliska Vaclavikova 1 , Jitka Carkova 1 , Rami Katra 2 , Petr Vlcek 3 , Daniela Kodetova 4 , Martin Chovanec 5 , Jana Drozenova 6 , Radoslav Matej 7 , Jaromir Astl 8 , Jiri Hlozek 8 , Jiri Soukup 9 , Bela Bendlova 1 & Josef Vcelak 1
1Institute of Endocrinology, Department of Molecular Endocrinology, Prague, Czech Republic; 22nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Department of Ear, Nose, and Throa, Prague, Czech Republic; 32nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Department of Nuclear Medicine and Endocrinology, Prague, Czech Republic; 42nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Department of Pathology and Molecular Medicine, Prague, Czech Republic; 53rd Faculty of Medicine, Charles University in Prague and University Hospital Kralovske Vinohrady, Department of Otorhinolaryngology, Prague, Czech Republic; 63rd Faculty of Medicine, Charles University in Prague and University Hospital Kralovske Vinohrady, Prague, Department of Pathology, Prague, Czech Republic; 73rd Faculty of Medicine, Charles University in Prague and University Hospital Kralovske Vinohrady, Department of Pathology, Prague, Czech Republic; 83rd Faculty of Medicine and Military University Hospital, Department of Otorhinolaryngology and Maxillofacial Surgery, Prague, Czech Republic; 93rd Faculty of Medicine and Military University Hospital, Prague, Department of Pathology, Prague, Czech Republic
JOINT3402
Objective: The NRAS Q61R variant is frequently observed in a range of thyroid tumors, including benign nodules, low-risk neoplasms, and malignant tumors such as follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma (PTC). The presence of the Q61R variant alone makes it challenging to distinguish between benign and malignant lesions.
Methods: This study investigated miRNA expression profiles in 12 PTC, four FTCs, five low-risk carcinomas, 11 benign nodules, and 12 healthy thyroid tissues free of genetic alterations. The miRNA libraries for NGS sequencing were prepared from RNA isolated from fresh-frozen thyroid tissues using the QIAseq miRNA Library Kit (Qiagen). To compare miRNA expression between NRAS benign and malignant tissues, as well as between NRAS-positive and healthy tissues the miRge3.0 tool and DESeq2 package in R were used.
Results: NRAS-positive samples displayed significant miRNA expression changes compared to healthy tissues, with 125 miRNAs altered (50 upregulated, 75 downregulated). Noteworthy upregulated miRNAs included hsa-miR-221-3p, hsa-miR-221-5p, hsa-miR-222-3p. When comparing NRAS-positive benign nodules to malignant tumors, we identified significant changes in the expression of 33 miRNAs. Malignant samples showed marked increases in miRNAs such as hsa-miR-520a-5p and hsa-miR-519d-3p, while hsa-miR-9-5p significantly decreased.
Conclusion: These data suggest distinct miRNA expression profiles that may help differentiate benign from malignant thyroid tumors with the NRAS Q61R variant. Supported by AZV NU21-01-00448 and MH CZ RVO 00023761..
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more